CMS Further Improves Reimbursement for Lutonix DCB for Outpatient Use
June 09 2015 - 10:50AM
Business Wire
C. R. Bard, Inc. (NYSE: BCR) today announced that the U.S.
Centers for Medicare and Medicaid Services (CMS) has improved the
pass-through payment for the Lutonix® drug-coated balloon (DCB)
under the Medicare hospital outpatient prospective payment system.
The purpose of the reimbursement is to cover additional cost to
U.S. hospitals for treating Medicare beneficiaries with the Lutonix
DCB in the outpatient setting. After further review, CMS determined
that costs associated with DCBs were not included in existing
reimbursement for percutaneous transluminal angioplasty, stenting,
or atherectomy procedures. Therefore, CMS is removing the device
offset charge from the calculation and will reimburse the full cost
of DCBs in these procedures. This reimbursement determination is
retroactive to April 1, 2015.
The Lutonix® 035 DCB—the first FDA-approved DCB— is an
angioplasty balloon coated with a therapeutic dose of the drug
paclitaxel, and also utilizes standard mechanical dilatation of the
vessel to restore blood flow for patients with peripheral arterial
disease (PAD) in the femoropopliteal arteries.
Timothy M. Ring, chairman and chief executive officer,
commented, “Today’s announcement is great news for patients. CMS
has recognized that the Lutonix® DCB meets an important patient
need and has moved quickly to provide full reimbursement for this
breakthrough technology in the outpatient setting.”
C. R. Bard, Inc. (www.crbard.com),
headquartered in Murray Hill, N.J., is a leading multinational
developer, manufacturer and marketer of innovative, life-enhancing
medical technologies in the fields of vascular, urology, oncology
and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current expectations, the
accuracy of which is necessarily subject to risks and
uncertainties. These statements are not historical in nature and
use words such as “anticipate”, “estimate”, “expect”, “project”,
“intend”, “forecast”, “plan”, “believe”, and other words of similar
meaning in connection with any discussion of future operating or
financial performance. Many factors may cause actual results to
differ materially from anticipated results including product
developments, sales efforts, income tax matters, the outcomes of
contingencies such as legal proceedings, and other economic,
business, competitive and regulatory factors. The company
undertakes no obligation to update its forward-looking statements.
Please refer to the Cautionary Statement Regarding Forward-Looking
Information in our March 31, 2015 Form 10-Q for more detailed
information about these and other factors that may cause actual
results to differ materially from those expressed or implied.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150609006301/en/
C. R. Bard, Inc.Investor Relations:Todd W.
Garner, 908-277-8065Vice President, Investor
RelationsorMedia Relations:Scott T. Lowry,
908-277-8365Vice President and Treasurer
Bard C R (NYSE:BCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bard C R (NYSE:BCR)
Historical Stock Chart
From Apr 2023 to Apr 2024